Compare Adaptive Biotechnologies Corp (ADPT) vs Crowdstrike Holdings Inc (CRWD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Crowdstrike Holdings Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.12 (market cap $3.33B), while Crowdstrike Holdings Inc trades at $189.37 (market cap $198.17B). The key difference: Crowdstrike Holdings Inc is far larger — about 59.5× Adaptive Biotechnologies Corp's market cap. Which is the better fit depends on your goals.
| ADPT | CRWD | |
|---|---|---|
Market Cap | $3.33B | $198.17B |
Sector | Health | Technology |
52-Week High | $22.37 | $199.38 |
52-Week Low | $10.24 | $87.56 |
Enterprise Value | $3.19B | $194.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
CrowdStrike (CRWD) trades at $194.62, up 0.43% today, with a strong technical outlook showing bullish momentum and key resistance at $199. The stock recently completed a 4-for-1 split, enhancing accessibility. Revenue growth accelerated to 26% year-over-year in Q1 2026, with EPS consistently beating estimates, though net margins remain negative. Analyst sentiment is overwhelmingly positive with 76% buy ratings and a $180.33 consensus target, despite premium valuations like a P/E of 765.
Outlook remains optimistic due to robust cybersecurity demand and AI-driven threats, but high valuation and profitability challenges pose risks. Investors should weigh growth potential against elevated multiples and competitive pressures in the sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Crowdstrike Holdings Inc
CrowdStrike Holdings provides cybersecurity products and services aimed at protecting organizations from cyberthreats. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, identity protection, and log management. CrowdStrike went public in 2019 and serves customers worldwide.
Read more on CRWD →
